secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inogen Inc (INGN)
CIK:        0001294133
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0000950170-25-004824
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inogen reports prelim Q4 rev $79M-$80M (+4-5%); FY24 rev $334.5M-$335.5M (+6%), beats guidance
--------------------------------------------------------------------------------

- Q4 2024 preliminary revenue of $79M-$80M, up 4-5% YoY.
- Full-year 2024 preliminary revenue of $334.5M-$335.5M, up 6% YoY, exceeding prior guidance of $329M-$331M.
- Driven by strong double-digit B2B revenue growth; DTC revenue stabilization ongoing.
- Launched Rove 4 and received FDA clearance for SIMEOX 200 during Q4.
- Official Q4/FY results and conference call scheduled for Feb 25, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1294133/000095017025004824/0000950170-25-004824-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1294133/000095017025004824/ingn-20250113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-004824

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer